BHCM
RCUS icon

Brevan Howard Capital Management’s Arcus Biosciences RCUS Stock Holding History

Brevan Howard Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42,113
Closed -$573K – 2195
2025
Q3 		$573K Buy
42,113
+30,141
+252% +$313K ﹤0.01% 1214
2025
Q2 		$97.5K Buy
+11,972
New +$102K ﹤0.01% 1784
2025
Q1 		– Sell
-14,279
Closed -$213K – 1403
2024
Q4 		$213K Buy
14,279
+3,957
+38% +$64.6K ﹤0.01% 892
2024
Q3 		$158K Sell
10,322
-20,641
-67% -$325K ﹤0.01% 1035
2024
Q2 		$472K Buy
+30,963
New +$500K ﹤0.01% 628

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Brevan Howard Capital Management's RCUS Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 42,113 shares — an estimated $573K sold.

Brevan Howard Capital Management first reported a position in RCUS in Q2 2024 and held it in 5 quarters. The position peaked at $573K in Q3 2025. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 42,113 Arcus Biosciences shares in Q4 2025, an estimated $573K.
  • Brevan Howard Capital Management first reported a position in Arcus Biosciences in Q2 2024 and held it in 5 quarters.
  • Brevan Howard Capital Management's Arcus Biosciences position peaked at $573K in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.